Log in

NYSEARCA:XBISPDR S&P Biotech ETF Stock Price, Forecast & News

$102.91
+0.83 (+0.81 %)
(As of 06/5/2020 04:00 PM ET)
Add
Today's Range
$101.24
Now: $102.91
$104.43
50-Day Range
$84.49
MA: $98.75
$106.05
52-Week Range
$62.94
Now: $102.91
$108.05
Volume5.75 million shs
Average Volume7.18 million shs
Market Capitalization$4.52 billion
P/E RatioN/A
Dividend Yield0.01%
BetaN/A
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index. SSgA Funds Management, Inc. is the Fund's investment advisor.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.46 out of 5 stars


Basic Details

Issuer SSgA
Fund NameSPDR S&P Biotech ETF
Tax ClassificationRegulated Investment Company
SymbolNYSEARCA:XBI
Inception Date1/31/2006
Fund ManagerMichael Feehily, Karl Schneider, Raymond Donofrio
Phone+1-866-7872257

Fund Focus

Asset ClassEquity
BenchmarkS&P Biotech Index
CategorySector
FocusHealth Care
Development LevelDeveloped Markets
RegionNorth America

Fund Statistics

Assets Under Management$4.42 billion
Average Daily Volume$6.94 million
Discount/Premium-0.07%

ETF Expenses

Management Fee0.35%
Other Expenses0.00%
Total Expenses0.35%
Fee Waiver0.00%
Net Expenses0.35%

Administrator, Advisor and Custodian

AdministratorSSGA Funds Management, Inc.
AdvisorSSgA Funds Management, Inc.
CustodianState Street Bank and Trust Company
DistributorState Street Global Advisors Funds Distributors, LLC
Transfer AgentState Street Bank and Trust Company
Trustee
Lead Market MakerVirtu Financial

Receive XBI News and Ratings via Email

Sign-up to receive the latest news and ratings for XBI and its competitors with MarketBeat's FREE daily newsletter.

Geographic Exposure of SPDR S&P Biotech ETF (NYSEARCA:XBI)
Currency Exposure of SPDR S&P Biotech ETF (NYSEARCA:XBI)
Sector Exposure of SPDR S&P Biotech ETF (NYSEARCA:XBI)
Industry Exposure of SPDR S&P Biotech ETF (NYSEARCA:XBI)

SPDR S&P Biotech ETF (NYSEARCA:XBI) Frequently Asked Questions

How has SPDR S&P Biotech ETF's stock been impacted by COVID-19 (Coronavirus)?

SPDR S&P Biotech ETF's stock was trading at $79.00 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, XBI shares have increased by 30.3% and is now trading at $102.91. View which stocks have been most impacted by Coronavirus.

How often does SPDR S&P Biotech ETF pay dividends? What is the dividend yield for SPDR S&P Biotech ETF?

SPDR S&P Biotech ETF announced a quarterly dividend on Friday, December 20th. Investors of record on Monday, December 23rd will be given a dividend of $0.0009 per share on Thursday, December 26th. This represents a $0.00 annualized dividend and a yield of 0.00%. The ex-dividend date is Friday, December 20th. View SPDR S&P Biotech ETF's dividend history.

Has SPDR S&P Biotech ETF been receiving favorable news coverage?

Press coverage about XBI stock has trended somewhat positive on Sunday, InfoTrie reports. The research group identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. SPDR S&P Biotech ETF earned a news impact score of 1.3 on InfoTrie's scale. They also assigned media stories about the exchange traded fund a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news aboutSPDR S&P Biotech ETF.

What other stocks do shareholders of SPDR S&P Biotech ETF own?

Based on aggregate information from My MarketBeat watchlists, some companies that other SPDR S&P Biotech ETF investors own include iShares Nasdaq Biotechnology ETF (IBB), NVIDIA (NVDA), Netflix (NFLX), Walt Disney (DIS), Intel (INTC), Alibaba Group (BABA), Gilead Sciences (GILD), Micron Technology (MU), Cisco Systems (CSCO) and Pfizer (PFE).

Who are SPDR S&P Biotech ETF's key executives?

SPDR S&P Biotech ETF's management team includes the following people:
  • James E. Ross, President, Trustee (Age 52)
  • Peter A. Ambrosini, Chief Compliance Officer (Age 69)
  • Michael P. Riley, Vice President (Age 44)
  • Gary L. French, Treasurer (Age 64)
  • John W. Clark, Assistant Treasurer (Age 46)
  • Matthew W. Flaherty, Assistant Treasurer (Age 42)
  • Chad C. Hallett, Assistant Treasurer of Street tracks series trust (Age 47)
  • Mary Moran Zeven, Secretary (Age 52)
  • Scott M. Zoltowski, Assistant Secretary (Age 44)
  • Dave Kelly, Independent Trustee

What is SPDR S&P Biotech ETF's stock symbol?

SPDR S&P Biotech ETF trades on the New York Stock Exchange (NYSE)ARCA under the ticker symbol "XBI."

Who are SPDR S&P Biotech ETF's major shareholders?

SPDR S&P Biotech ETF's stock is owned by a number of institutional and retail investors. Top institutional shareholders include JPMorgan Chase & Co. (20.93%), Morgan Stanley (17.79%), Healthcare of Ontario Pension Plan Trust Fund (4.89%), Wells Fargo & Company MN (1.90%), SG Americas Securities LLC (1.24%) and Two Sigma Advisers LP (0.90%).

Which major investors are selling SPDR S&P Biotech ETF stock?

XBI stock was sold by a variety of institutional investors in the last quarter, including Healthcare of Ontario Pension Plan Trust Fund, Wells Fargo & Company MN, Two Sigma Advisers LP, HBK Investments L P, Orbimed Advisors LLC, Thrivent Financial for Lutherans, Chatham Capital Group Inc., and Carnegie Capital Asset Management LLC.

Which major investors are buying SPDR S&P Biotech ETF stock?

XBI stock was bought by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Morgan Stanley, SG Americas Securities LLC, tru Independence LLC, Meitav Dash Investments Ltd., Advisor Group Holdings Inc., Private Advisor Group LLC, and CMH Wealth Management LLC.

How do I buy shares of SPDR S&P Biotech ETF?

Shares of XBI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is SPDR S&P Biotech ETF's stock price today?

One share of XBI stock can currently be purchased for approximately $102.91.

How big of a company is SPDR S&P Biotech ETF?

SPDR S&P Biotech ETF has a market capitalization of $4.52 billion.

What is SPDR S&P Biotech ETF's official website?

The official website for SPDR S&P Biotech ETF is www.spdrs.com.

How can I contact SPDR S&P Biotech ETF?

SPDR S&P Biotech ETF's mailing address is One Lincoln Street, Boston, 02111, United States. The exchange traded fund can be reached via phone at +1-866-7872257.

This page was last updated on 6/7/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.